| abstract |
This invention provides novel formulations for N-[4-(5H-pyrrolo[2,1- c][1,4]benzodiazepin-10(11H)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2-methyl- benzamide, or a pharmaceutically acceptable salt thereof, and processes for making them, the formulations comprising from about 1 % to about 20 % of active ingredient, from about 1 % to about 18 % of a surfactant component, from about 50 % to about 80 % of a component of one or more polyethylene glycols, from about 1 % to about 20 % of a component of one or more sucrose fatty acid esters and/or polyvinylpyrrolidone and, optionnaly, one or more pharmaceutically acceptable preservatives or antioxidants. |